BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline
BioCryst Pharmaceuticals (NASDAQ:BCRX) executives highlighted the company's transition to profitability, continued growth of its hereditary angioedema (HAE) franchise, and progress on newly acquired...